Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 78 recruiting now early-phase tilt #65 of 28,707 conditions

Epilepsy: early-phase trial registry

78 of 164 indexed Epilepsy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #65 of 28,707 conditions by registered trial count.

164 US clinical trials · 78 currently recruiting · #65 of 28,707 conditions by registered trial count

Epilepsy: 164 US clinical trials tracked, 78 recruiting.

Epilepsy is the subject of 164 registered US clinical trials on ClinicalTrials.gov, 78 of them currently open to new participants. 21 are in Phase 3-4 (later-stage) and 39 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Neurological Disorders and Stroke (NINDS), running 9 of these trials.

Enrollment posture brief

Registry condition epilepsy

OPEN 78 | RECR 48% | LATE 21 | EARLY 39 | RANK #65 | SPON 9

Nearest open-share peer: Microbial Colonization (48% recruiting · 21 trials)

Epilepsy (this)48%Gastric Cancer45.3%Neoplasms31.3%Parkinson's Disease26.1%Bipolar Disorder22.7%
Open-enrollment share among volume-matched conditions near Epilepsy

Epilepsy lists 78 open slots (48% of 164 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Epilepsy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Epilepsy is recruiting above its size-band peers.

    78 of 164 indexed trials (47.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Epilepsy trials is spread across many organizations.

    National Institute of Neurological Disorders and Stroke (NINDS) accounts for 9 of 164 trials (5.5%). 95 distinct sponsors appear on at least one study for this condition label.

  3. Most Epilepsy trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 161 trials that report a genuine target (sentinel values excluded). 103 of those (64%) plan for fewer than 100 participants.

  4. Epilepsy research is mostly interventional.

    120 interventional and 44 observational studies make up this index (73.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 123Phase 216Phase 314Phase 47

Open and recent trials

164 total, page 4 of 4

COMPLETED 17 participants

In Vivo Imaging of Therapeutic Electric Current Flow

University of Florida

NCT02453763

COMPLETED Phase 1 14 participants

Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy

Mayo Clinic

NCT01703143

COMPLETED Phase 1 12 participants

Treatment Development of Triheptanoin (G1D)

Juan Pascual

NCT03041363

COMPLETED Phase 2 11 participants

Efficacy of YKP3089 in Patients With Photosensitive Epilepsy

SK Life Science

NCT00616148

COMPLETED 11 participants

Seizure Detection and Warning System in Epilepsy Patients

Brain Sentinel

NCT02555410

COMPLETED Phase 1 8 participants

Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite

GlaxoSmithKline

NCT01480609

COMPLETED Phase 2 7 participants

CX-8998 for Absence Seizures

Jazz Pharmaceuticals

NCT03406702

COMPLETED Phase 4 6 participants

Levetiracetam for Benign Rolandic Epilepsy

Johns Hopkins University

NCT00181116

COMPLETED NA 5 participants

Electroencephalography (EEG) and Deep Brain Stimulation (DBS) in Epilepsy

Weill Medical College of Cornell University

NCT00194870

COMPLETED NA 2 participants

Presurgical Motor Mapping With Transcranial Magnetic Stimulation (TMS)

NYU Langone Health

NCT02741193

COMPLETED Phase 1 1 participants

High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy

NYU Langone Health

NCT02264652

COMPLETED

Pediatric Epilepsy Database

University of Alabama at Birmingham

NCT00204360

COMPLETED Phase 4

Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy

National Center for Research Resources (NCRR)

NCT00004637

COMPLETED Phase 2

E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Eisai

NCT00144690

← Previous Page 4 of 4

Phase Distribution

PhaseTrial count
Phase 1 23
Phase 2 16
Phase 3 14
Phase 4 7

Named interventions

Most-linked intervention names on Epilepsy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
14 trials
Project UPLIFT Behavioral
3 trials
Brivaracetam Drug
3 trials
Levetiracetam Drug
3 trials
Lamotrigine Drug
3 trials
Diazepam Buccal Film Drug
2 trials
oxcarbazepine Drug
2 trials
Individualized Adherence Feedback Report Behavioral
2 trials

US sites by state

Facility locations filed on Epilepsy trials. A trial with sites in several states counts in each.

New York 38 trials
Massachusetts 35 trials
California 31 trials
Florida 30 trials
Minnesota 29 trials
Texas 28 trials
Ohio 26 trials
Maryland 26 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Epilepsy page

164 registered trials, 78 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Epilepsy condition card totals 164 registered trials; most-linked intervention Placebo; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.